Rapid Micro Biosystems (NASDAQ:RPID) (NASDAQ: RPID) develops and commercializes rapid microbial detection and identification systems for quality control laboratories in the pharmaceutical, biotechnology, medical device and consumer health industries. Founded in 2001 and headquartered in Woburn, Massachusetts, the company offers automated platforms that enable manufacturers to detect microbial contamination more quickly than traditional culture-based methods, helping to accelerate product release and improve patient safety.
The company’s flagship RAPID™ instruments combine proprietary fluorescent staining, high‐resolution imaging and advanced software analytics to provide quantitative and qualitative microbial testing results in hours rather than days. Rapid Micro’s product suite includes consumables, reagents and accessories designed to streamline sample preparation and support compliance with global regulatory standards such as FDA 21 CFR Part 11 and EU Annex 1.
In addition to its core instrumentation and consumable offerings, Rapid Micro Biosystems provides installation, validation, training and ongoing technical support to ensure seamless integration into existing quality control workflows. The company’s dedicated field service and applications teams work closely with clients to qualify methods, optimize protocols and maintain compliance across multiple geographies.
Rapid Micro Biosystems went public in 2020 and is listed on the NASDAQ under the symbol RPID. The company serves a global customer base spanning North America, Europe and the Asia-Pacific region. Led by a seasoned management team with deep expertise in microbiology, engineering and regulatory affairs, Rapid Micro is positioned as a strategic partner in the digital transformation of pharmaceutical and life sciences manufacturing.
